Approved Study Database
| Ref. No. | Scientific Title | Principal investigator |
|---|---|---|
| 2026.135 | An Open-Label, Single-Arm, 3-Year Extension Study to Evaluate Safety and Tolerability of Tinlarebant in Subjects with Stargardt Disease | Dr. WONG Raymond Lai Man |
| 2026.269 | Exploratory Study of Ianalumab in Adults with Primary Immune Thrombocytopenia (ITP) and Warm-antibody Autoimmune Hemolytic Anemia (wAIHA) who Have Previously Benefited from Ianalumab (VAY RE-HIT) | Dr. Wong Raymond Siu Ming |
| 2024.595 | A Phase III, Multicentre, Randomised, Open-label Study to Compare the Efficacy and Safety of AZD0486 plus Rituximab versus Chemotherapy plus Rituximab in Previously Untreated Participants with Follicular Lymphoma (SOUNDTRACK-F1) |
Dr. WONG Raymond Siu Ming 王紹明 |
| 2024.390 | The disease epidemiology and treatment of haemophilia A and B patients in Hong Kong |
Dr. WONG Raymond Siu Ming 王紹明 |
| 2025.284 | A Retrospective Analysis of Risk Factors, Treatments and Outcomes of Cancer-associated Venous Thromboembolism in Chinese Patients | Dr. WONG Raymond Siu Ming |
| 2024.694 | A Modular Phase II, Single-arm, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Surovatamig (AZD0486) in Participants with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (SOUNDTRACK-B) |
Dr. WONG Raymond Siu Ming 王紹明 |
| 2026.077 | EVALUATING EFFECTIVENESS AND SAFETY OF GLOFITAMAB BASED SECOND-LINE THERAPY IN CHINESE ADULT PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA: A PROSPECTIVE, OBSERVATIONAL, MULTICENTER, COHORT STUDY | Dr. Wong Raymond Siu Ming |
| 2024.660 | Phase 3b, Open-label, Multicenter, Single-dose Study Investigating Efficacy and Safety of CSL222 (Etranacogene Dezaparvovec) Gene Therapy Administered to Adult Subjects with Severe or Moderately Severe Hemophilia B with Detectable Pretreatment AAV5 Neutralizing Antibodies | Dr. WONG Raymond Siu Ming |
| 2025.862 | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Revumenib in Combination with Intensive Chemotherapy in Participants with Newly Diagnosed AML with an NPM1 mutation (REVEAL-ND NPM1) |
Dr. Wong Raymond Siu Ming 王紹明 |
| 2024.596 | A Phase 3, Double-Blind, Randomized, Placebo-Controlled Trial of Quizartinib Administered in Combination with Induction and Consolidation Chemotherapy and Administered as Maintenance Therapy in Adult Patients with Newly Diagnosed FLT3-ITD Negative Acute Myeloid Leukemia (QuANTUM-Wild) | Dr. WONG Raymond Siu Ming |
| 2012.400 | Paroxysmal Nocturnal Hemoglobinuria (PNH) registry | Dr. WONG Raymond Siu Ming |
| 2009.588 | A Phase I/Iia, Open-Label, Crossover, Dose-Escalation, and Multi-Center Study to Determine the Safety, Tolerability, and Pharmacokinetics of a Single Intravenous Injection of rFVIIIFc in Previously Treated Patients with Severe Hemphilia A | Dr. Wong Raymond Siu Ming |
| 2022.476 | A phase III, randomized, double-blind study of ianalumab (VAY736) versus placebo in addition to first-line corticosteroids in primary immune thrombocytopenia (VAYHIT1) |
Dr. WONG Raymond Siu Ming 王紹明 |
| 2022.411 | A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Depemokimab in Adults with Hypereosinophilic Syndrome (HES) |
Dr. WONG Raymond Siu Ming 王紹明 |
| 2021.521 | A Randomized, Open-Label, Multicenter, Parallel-Group Study to Evaluate the Efficacy, Safety, and Tolerability of Oral BCX9930 Monotherapy for the Treatment of Paroxysmal Nocturnal Hemoglobinuria in Subjects with Inadequate Response to C5 Inhibitor Therapy |
Dr. WONG Raymond Siu Ming 王紹明 |
| 2022.655 | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Acalabrutinib in Combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Subjects ≤75 Years with Previously Untreated Non-Germinal Center Diffuse Large B-Cell Lymphoma |
Dr. WONG Raymond Siu Ming 王紹明醫生 |
| 2020.576 | A Study to Describe the Real-world Use of Dasatinib Treatment for Patients with Philadelphia Chromosome Positive Chronic Myeloid Leukaemia (CML) | Dr. WONG Raymond Siu Ming |
| 2021.710 | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Magrolimab versus Placebo in Combination with Venetoclax and Azacitidine in Newly Diagnosed, Previously Untreated Patients with Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy |
Dr. WONG Raymond Siu Ming 王紹明 |
| 2021.462 | A Randomized, Double-Blind, Multicenter, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, and Tolerability of Oral BCX9930 Monotherapy for the Treatment of Paroxysmal Nocturnal Hemoglobinuria |
Dr. WONG Raymond Siu Ming 王紹明 |
| 2021.152 | A PHASE III, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED, MULTICENTER STUDY EVALUATING THE SAFETY, PHARMACOKINETICS, PHARMACODYNAMICS, AND EFFICACY OF CROVALIMAB VERSUS ECULIZUMAB IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) CURRENTLY TREATED WITH COMPLEMENT INHIBITORS |
Dr. WONG Raymond Siu Ming 王紹明 |
| 2023.152 | A Multicenter, Open-Label, First-In-Human, Multiple Expansion Cohort, Phase 1/2 Study to Evaluate the Safety and Efficacy of DR-01 in Adult Subjects with Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas |
Dr. WONG Raymond Siu Ming 王紹明 |
| 2020.692 | A PHASE 3, DOUBLE-BLIND, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF LUSPATERCEPT (ACE-536) VERSUS PLACEBO IN SUBJECTS WITH MYELOPROLIFERATIVE NEOPLASM-ASSOCIATED MYELOFIBROSIS ON CONCOMITANT JAK2 INHIBITOR THERAPY AND WHO REQUIRE RED BLOOD CELL TRANSFUSIONS The “INDEPENDENCE” Trial |
Dr. WONG Raymond Siu Ming 王紹明 |
| 2021.193 | ENHANCE: A Randomized, Double-blind, Multicenter Study Comparing Magrolimab in Combination with Azacitidine versus Azacitidine Plus Placebo in Treatment-naïve Patients with Higher Risk Myelodysplastic Syndrome |
Dr. WONG Raymond Siu Ming 王紹明 |
| 2022.072 | A Phase 3, Randomized, Double-Blind, Active-Control Study of Pelabresib (CPI-0610) and Ruxolitinib vs. Placebo and Ruxolitinib in JAKi Treatment Naive MF Patients |
Dr. WONG Raymond Siu Ming 王紹明 |
| 2021.151 | A PHASE III, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF CROVALIMAB VERSUS ECULIZUMAB IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) NOT PREVIOUSLY TREATED WITH COMPLEMENT INHIBITORS |
Dr. WONG Raymond Siu Ming 王紹明 |
| 2022.171 | A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL) |
Dr. WONG Raymond Siu Ming 王紹明 |
| 2021.267 | A Phase 3, Randomized, Open-Label Study Evaluating the Safety and Efficacy of Magrolimab in Combination with Azacitidine versus Physician’s Choice of Venetoclax in Combination with Azacitidine or Intensive Chemotherapy in Previously Untreated Patients with TP53 Mutant Acute Myeloid Leukemia |
Dr. WONG Raymond Siu Ming 王紹明 |
| 2021.182 | A Randomized, Open-Label, Two-Arm Study to Evaluate the Safety, Efficacy, and Pharmacodynamic Effects of Pozelimab and Cemdisiran Combination Treatment in Patients with Paroxysmal Nocturnal Hemoglobinuria Who Have Received Pozelimab Monotherapy |
Dr. WONG Raymond Siu Ming 王紹明 |
| 2007.430 | A Worldwide, Observational Registry Collecting Longitudinal Data on the Management of Chronic Myelogenous Leukemia (CML) Patients (The World CML Registry) in Routine Practice | WONG Raymond Siu Ming |
| 2009.220 | Study PMA112509, a Phase I/II Study of Eltrombopag in Thrombocytopenic Subjects with Advanced Myelodysplastic Syndrome (MDS) or secondary Acute Myeloid Leukemia after MDS (sAML/MDS) | Dr. Wong Raymond Siu Ming |
| 2009.457 | An open-label, multi-center, three arm randomized, phase III study to compare the efficacy and safety of RO5072759 +chlorambucil (GClb), rituximab + chlorambucil (RClb) or chlorambucil (Clb) alone in previously untreated CLL patients with comorbidities | Dr. WONG Raymond Siu Ming |
| 2006.286 | EXTEND (Eltrombopag eXTENded Dosing Study): An Extension Study of Eltrombopag Olamine (SB-497115-GR) in Adults, with Idiopathic Thrombocytopenic Purpura (ITP), Previously Enrolled in An Eltrombopag Study | Prof. WONG Raymond Siu Ming |
| 2008.068 | A Phase 1 / 2 Study of CMC-544 Administered in Combination with Rituximab in Subjects with Follicular or Diffuse Large B-Cell Non-Hodgkin’s Lymphoma | Prof. WONG Raymond Siu Ming |
| 2009.488 | A study of the pharmacokinetics of Nilotinib (Tasigna) in Chinese patients with imatinib-resistant and/or | Dr. WONG Raymond Siu Ming |
| 2012.419 | An Open-label, Multicenter Study to Evaluate the Safety of Long-term Treatment with Siltuximab in Subjects with Multicentric Castleman's Disease | Dr. WONG Raymond Siu Ming |
| 2009.489 | A multi-center, randomized, double-blind, placebo-controlled clinical trial of deferasirox in patients with myelodysplastic syndromes (low/int-1 risk) and tranfusional iron overload (TELESTO) | Dr. WONG Raymond Siu Ming |
| 2012.257 | A Randomized, Double-Blind, Multicenter Study of Denosumab Compared With Zoledronic Acid in the Treatment of Bone Disease in Subjects with Newly Diagnosed Multiple Myeloma | Dr. WONG Raymond Siu Ming |
| 2014.111 | A Phase III, case series clinical study of the reversal of the anticoagulant effects of dabigatran by intravenous administration of 5.0 g idarucizumab (BI 655075) in patients treated with dabigatran etexilate who have uncontrolled bleeding or require emergency surgery or procedures. | Dr. WONG Raymond Siu Ming |
| 2013.430 | AN OPEN-LABEL BOSUTINIB TREATMENT EXTENSION STUDY FOR SUBJECTS WITH CHRONIC MYELOID LEUKEMIA (CML) WHO HAVE PREVIOUSLY PARTICIPATED IN BOSUTINIB STUDIES B1871006 OR B1871008 | Dr. WONG Raymond Siu Ming |
| 2009.308 | A Phase 2 Study of Inotuzumab Ozogamicin (CMC-544) in Subjects With Indolent Non-Hodgkin’s Lymphoma (NHL) That is Refractory to or has Relapsed After Rituximab and Chemotherapy or Radioimmunotherapy | Dr. WONG Raymond Siu Ming |
| 2010.176 | B-LONG: An Open-Label, Multicenter Evaluation of the Safety, Pharmacokinetics, and Efficacy of Recombinant, Long-acting Coagulation Factor IX Fc fusion (rFIXFc) in the Prevention and Treatment of Bleeding in Previously Treated Subjects With Severe Hemophilia B |
Dr. Wong Raymond Siu Ming Raymond Siu Ming WONG |
| 2011.538 | An Open-Label, Multicenter Evaluation of the Long-Term Safety and Efficacy of Recombinant Human Coagulation Factor VIII Fusion Protein (rFVIIIFc) in the Prevention and Treatment of Bleeding Episodes in Previously Treated Subjects With Hemophilia A | Dr. WONG Raymond Siu Ming |
| 2007.017 | LENS | Dr. WONG Raymond Siu Ming |
| 2009.573 | An Open-label, Phase 1 Study of R-CVP or R-GDP in Combination With Inotuzumab Ozogamicin in Subjects With CD22-Positive Non-Hodgkin’s Lymphoma | Dr. Wong Raymond Siu Ming |
| 2010.030 | A multicenter, randomized, double-blind, placebo controlled phase III study of panobinostat in combination with bortezomib and dexamethasone in patients with relapsed multiple myeloma | Dr. WONG Raymond Siu Ming |
| 2007.186 | A Phase 3, Randomized, Double-Blind, Parallel-Group, Multi-Center Study of the Safety and Efficacy of Apixaban for Prophylaxis of Venous Thromboembolism in Acutely I11 Medical Subjects During and Following Hospitalization | Dr. WONG Raymond Siu Ming |
| 2011.479 | An Open-Label, Multicenter Evaluation of the Long-Term Safety and Efficacy of Recombinant Human Coagulation Factor IX Fusion Protein (rFIXFc) in the Prevention and Treatment of Bleeding Episodes in Previously Treated Subjects With Hemophilia B | Dr. WONG Raymond Siu Ming |
| 2014.112 | Study 200170: A Rollover Study to Provide Continued Treatment with Eltrombopag. | Dr. WONG Raymond Siu Ming |
| 2009.494 | A Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of CNTO 328 (Anti-IL-6 Monoclonal Antibody) Plus Best Supportive Care Compared With Best Supportive Care in Subjects With Multicentric Castleman Disease | Dr. WONG Raymond Siu Ming |
| 2011.395 | A Three-part Study of Eltrombopag in Thrombocytopenic Subjects with Myelodysplastic Syndromes or Acute Myeloid Leukemia (Part 1: open-label, Part 2: randomized, double-blind, Part 3: extension). | Dr. WONG Raymond Siu Ming |
Page 256 of 289.